Urology
Volume 69, Issue 3 , Pages 500-504 , March 2007

Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer

  • Juan Morote

      Affiliations

    • Department of Urology, Vall d’Hebron Hospital, Autónoma University School of Medicine, Barcelona, Spain
    • ,
  • Jacques Planas Morin

      Affiliations

    • Department of Urology, Vall d’Hebron Hospital, Autónoma University School of Medicine, Barcelona, Spain
    • Corresponding Author InformationReprint requests: Jacques Planas Morin, M.D., Department of Urology, Vall d’Hebron University Hospital, P. Vall d’Hebron 119-129, Barcelona 08035, Spain.
    • ,
  • Anna Orsola

      Affiliations

    • Department of Urology, Vall d’Hebron Hospital, Autónoma University School of Medicine, Barcelona, Spain
    • ,
  • Jose M. Abascal

      Affiliations

    • Department of Urology, Vall d’Hebron Hospital, Autónoma University School of Medicine, Barcelona, Spain
    • ,
  • Carles Salvador

      Affiliations

    • Department of Urology, Vall d’Hebron Hospital, Autónoma University School of Medicine, Barcelona, Spain
    • ,
  • Enrique Trilla

      Affiliations

    • Department of Urology, Vall d’Hebron Hospital, Autónoma University School of Medicine, Barcelona, Spain
    • ,
  • Carles X. Raventos

      Affiliations

    • Department of Urology, Vall d’Hebron Hospital, Autónoma University School of Medicine, Barcelona, Spain
    • ,
  • Lluis Cecchini

      Affiliations

    • Department of Urology, Vall d’Hebron Hospital, Autónoma University School of Medicine, Barcelona, Spain
    • ,
  • Gloria Encabo

      Affiliations

    • Department of Nuclear Medicine, Vall d’Hebron Hospital, Autónoma University School of Medicine, Barcelona, Spain
    • ,
  • Jaume Reventos

      Affiliations

    • Basic Research Unit, Vall d’Hebron Hospital, Autónoma University School of Medicine, Barcelona, Spain

Received 20 July 2006 ,Accepted 16 November 2006.

References 

  1. Holzbeierlein JM, McLaughlin MD, Thrasher JB. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol. 2004;14:177–183
  2. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol. 1997;157:439–444
  3. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–164
  4. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005–1007
  5. Amin S, Felson DT. Osteoporosis in men. Rheum Dis Clin North Am. 2001;27:19–47
  6. Gilbert SM, McKiernan JM. Epidemiology of male osteoporosis and prostate cancer. Curr Opin Urol. 2005;15:23–27
  7. Pouilles JM, Tremollieres F, Ribot C. Variability of vertebral and femoral postmenopausal bone loss: a longitudinal study. Osteoporosis Int. 1996;6:320–324
  8. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948–955
  9. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–2012
  10. Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87:3656–3661
  11. Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161:1219–1222
  12. Higano CS. Management of bone loss in men with prostate cancer. J Urol. 2003;170:S59–S63
  13. Eriksson S, Eriksson A, Stege R, et al. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int. 1995;57:97–99
  14. Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer. 2001;92:1444–1450
  15. Diamond T, Campbell J, Bryant C, et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer. 1998;83:1561–1566
  16. Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181–186
  17. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167:2361–2367
  18. Morote J, Orsola A, Abascal J, et al. Bone mineral density changes in prostate cancer patients during the first two years of androgen suppression. J Urol. 2006;175:1679–1683
  19. Morote J, Martinez E, Trilla E, et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol. 2003;44:661–665
  20. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis (report of a WHO Study Group). World Health Organ Tech Rep Ser. 1994;843:1–129
  21. Kiratli BJ, Srinivas S, Perkash I, et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001;57:127–132
  22. Bruder JM, Ma JZ, Basler JW, et al. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology. 2006;67:152–155
  23. Miller PD. Abstracts from the 2005 ISCD Annual Meeting. J Clin Densitom. 2005;8:228–249
  24. Smith MR, McGovern FJ, Fallon MA, et al. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer. 2001;91:2238–2245
  25. Hussain SA, Weston R, Stephenson RN, et al. Immediate dual energy x-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int. 2003;92:690–694
  26. Conde FA, Sarna L, Oka RK, et al. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004;64:335–340
  27. Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 1999;54:607–611

PII: S0090-4295(06)02517-9

doi: 10.1016/j.urology.2006.11.002

Urology
Volume 69, Issue 3 , Pages 500-504 , March 2007

Article Tools

* Image Usage & Resolution